+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05059444

Observation of Residual Cancer Using Guardant Reveal Blood Test Tracking Cancer Recurrence in Early-Stage Solid Tumors An Observational Study by Guardant Health

Led by Guardant Health, Inc. · Updated on 2026-09-14

2285

Participants Needed

57

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new blood test called Guardant Reveal to detect cancer recurrence in people treated for early-stage solid tumors. The study focuses on linking blood test results to clinical outcomes to prove its usefulness in detecting if cancer comes back. This research involves various types of cancers, including bladder, lung, breast, melanoma, gastrointestinal, ovarian, and others. Participants provide blood samples at enrollment and during regular clinical visits for up to 3 years, aligning with their standard follow-up care. The study includes several cancer groups defined by cancer type and stage. The blood samples are collected 3 to 12 weeks after treatment such as surgery or chemotherapy. This observational study monitors patients without altering their usual care. During the study, participants undergo routine follow-ups and provide clinical data and blood samples to help researchers track cancer recurrence. Researchers measure outcomes like time without distant recurrence over 3 years and test accuracy measures including sensitivity, specificity, and predictive values. The study is led by Guardant Health, Inc. and continues through August 2030, aiming to gather long-term data on the tests performance.

CONDITIONS

Brief Title

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Research Team

C

Clinical Trial Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here